COVID-19 infection manifesting as a severe gastroparesis flare: A case report

Jun Song, Rajiv Bhuta, Kamal Baig, Henry P Parkman, Zubair Malik, Jun Song, Rajiv Bhuta, Kamal Baig, Henry P Parkman, Zubair Malik

Abstract

Rationale: Coronavirus disease 2019 (COVID-19) is a disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which commonly presents with symptoms including fever, cough, and dyspnea. More recently, however, some patients have tested positive for COVID-19 after developing gastrointestinal (GI) symptoms either solely or in conjunction with respiratory symptoms. This may be due to SARS-CoV-2 infection of the GI tract. In patients with chronic GI illnesses, COVID-19 may initially present as a flare of their underlying GI conditions as viruses have historically been implicated in exacerbations of GI disorders, including gastroparesis.

Patient concerns: We report a case of a 37-year-old female with a history of diabetic gastroparesis who presented to the Emergency Department (ED) with nausea and vomiting similar to her gastroparesis flares.

Diagnoses: Her symptoms in the ED failed to improve with fluids and anti-emetic medications. After developing a fever, she was tested and found to be positive for COVID-19.

Interventions: She was started on antibiotic, steroid, and antiviral medications.

Outcomes: Her symptoms improved, her fever defervesced on day 4 of hospitalization, and she was discharged on day 5 of hospitalization. The patient reported symptom improvement at a follow-up outpatient gastroenterology visit 2 months after hospitalization.

Lessons: To the best of our knowledge, at the present time, this is the first report of a patient with COVID-19 presenting with signs and symptoms of a gastroparesis flare. This case illustrates that COVID-19 may present in an exacerbation of symptoms of an underlying disorder, such as a severe gastroparesis flare, in a patient with underlying gastroparesis. Initial presentation of these patients manifesting as a flare of their chronic GI disease, more severe than usual, should prompt an index of suspicion for COVID-19.

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Figures

Figure 1
Figure 1
CT Chest shows multifocal lower lung predominant peripheral bronchocentric ground glass opacities (red arrows) compatible with viral/atypical pneumonia.

References

    1. Song JH, Bhuta R, Baig K, et al. . S3020 COVID-19 manifesting as a gastroparesis flare: a case report. Am J Gastroenterol 2020;115:S1591–1591.
    1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;doi:10.1016/j.jaut.2020.102433.
    1. Emami A, Javanmardi F, Pirbonyeh N, et al. . Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Arch Acad Emerg Med 2020.
    1. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol 2020;doi:10.1111/jgh.15047.
    1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;doi:10.1016/S0140-6736(20)30183-5.
    1. Cholankeril G, Podboy A, Aivaliotis VI, et al. . High prevalence of concurrent gastrointestinal manifestations in patients with SARS-CoV-2: early experience from California. Gastroenterology 2020;doi:10.1053/j.gastro.2020.04.008.
    1. Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal–oral transmission. Gastroenterology 2020;doi:10.1053/j.gastro.2020.02.054.
    1. Han C, Duan C, Zhang S, et al. . Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am J Gastroenterol 2020.
    1. Chen L, Lou J, Bai Y, et al. . COVID-19 disease with positive fecal and negative pharyngeal and sputum viral tests. Am J Gastroenterol 2020;doi:10.14309/ajg.0000000000000610.
    1. Cai Q, Huang D, Yu H, et al. . COVID-19: abnormal liver function tests. J Hepatol 2020;73:566–74.
    1. Xiao F, Tang M, Zheng X, et al. . Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020;doi:10.1053/j.gastro.2020.02.055.
    1. Leung JM, Yang CX, Tam A, et al. . ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 2020;doi:10.1183/13993003.00688-2020.
    1. Zhou J, Li C, Zhao G, et al. . Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv 2017;doi:10.1126/sciadv.aao4966.
    1. Shi X, Gong E, Gao D, et al. . Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases. Am J Gastroenterol 2005;doi:10.1111/j.1572-0241.2005.40377.x.
    1. Abdullah ASM, Tomlinson B, Cockram CS, et al. . Lessons from the severe acute respiratory syndrome outbreak in Hong Kong. Emerg Infect Dis 2003;doi:10.3201/eid0909.030366.
    1. Yang J, Zheng Y, Gou X, et al. . Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis. Int J Infect Dis 2020;doi:10.1016/j.ijid.2020.03.017.
    1. Chen W, Lan Y, Yuan X, et al. . Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect 2020;9:469–73.
    1. Muus C, Luecken MD, Eraslan G, et al. . Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. bioRxiv 2020;doi:10.1101/2020.04.19.049254.
    1. Fan Z, Chen L, Li J, et al. . Clinical features of COVID-19-related liver damage. SSRN Electron J 2020;doi:10.2139/ssrn.3546077.
    1. Uppalapati SS, Ramzan Z, Fisher RS, et al. . Factors contributing to hospitalization for gastroparesis exacerbations. Dig Dis Sci 2009;doi:10.1007/s10620-009-0975-1.
    1. Oh JJ, Kim CH. Gastroparesis after a presumed viral illness: clinical and laboratory features and natural history. Mayo Clin Proc 1990;doi:10.1016/S0025-6196(12)65125-8.
    1. Bityutskiy LP, Soykan I, McCallum RW. Viral gastroparesis: a subgroup of idiopathic gastroparesis clinical characteristics and long-term outcomes. Am J Gastroenterol 1997.
    1. Parkman HP. Idiopathic gastroparesis. Gastroenterol Clin North Am 2015;doi:10.1016/j.gtc.2014.11.015.
    1. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006;doi:10.1111/j.1572-0241.2006.00869.x.
    1. Kim JJ, Simpson N, Klipfel N, et al. . Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci 2010;doi:10.1007/s10620-010-1126-4.
    1. Criscuoli V, Rizzuto MR, Cottone M. Cytomegalovirus and inflammatory bowel disease: Is there a link? World J Gastroenterol 2006;doi:10.3748/wjg.v12.i30.4813.
    1. Usai-Satta P, Bellini M, Morelli O, et al. . Gastroparesis: new insights into an old disease. World J Gastroenterol 2020;26:2333–48.
    1. Potter TG, Snider KR. Azitromicina en el tratamiento de gastroparesis. Ann Pharmacother 2013;47:411–5.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir